The person shown here is a basic user of this site. He or she may be contacted directly for language-related services.
|
Working languages: English to Latvian
Russian to Latvian |
| Doroteja
Latvia Local time: 16:33 EET (GMT+2)
Native in: English  , Latvian | |
Pharmaceutical translations | Freelancer,  Verified site user | | Translation, Editing/proofreading, Project management | | Specializes in: | | Other | Linguistics | | Medical: Pharmaceuticals | Chemistry; Chem Sci/Eng | | Cosmetics, Beauty | Medical: Instruments | | Biology (-tech,-chem,micro-) | Medical: Health Care | | Medical: Cardiology | Medical (general) |
| Also works in: | | Livestock / Animal Husbandry |
More Less | | Questions answered: 197, Questions asked: 15 Easy / 1103 PRO, PRO-level points: 347 | 3 entries
More Less | Sample translations submitted: 1| English to Latvian: Pharmacodynamic properties | Source text - English
Pharmacodynamic properties
Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4 subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Specifically, natalizumab binds to the α4β1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion molecule 1 (VCAM 1), and ligands osteopontin, and an alternatively spliced domain of fibronectin, connecting segment 1 (CS 1). Natalizumab blocks the interaction of α4β7 integrin with the mucosal addressin cell adhesion molecule 1 (MadCAM 1). A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of α4 expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.
In Crohn’s disease the interaction of both the 41 and 47 integrins with the endothelial receptors VCAM-1 and MadCAM-1 are important contributors to the chronic inflammation that is a characteristic of the disease. MadCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to gut lymph tissue found in Peyer’s patches. Under normal conditions, VCAM-1 is not normally expressed on gut endothelial cells. However in the presence of pro-inflammatory cytokines, VCAM-1 is upregulated in response to inflammatory cytokines in the setting of Crohn’s disease. Disruption of these cell adhesion molecule interactions prevents trafficking of mononuclear leukocytes across the endothelium and into the parenchymal tissue. In addition, the inhibition of the 4-subunit blocks the interaction of leukocytes with the gut extracellular matrix, including osteopontin and epitopes of fibronectin (FN). This may help suppress existing inflammation within the gut tissue.
| Translation - Latvian
Farmakodinamiskās īpašības
Natalizumabs ir selektīvas molekulārās adhēzijas inhibitors, un tas piesaista cilvēka integrīna α4-subvienību, kura ievērojamos daudzumos ir sastopama uz visu leikocītu, izņemot neitrofīlo virsmas. Natalizumabs specifiski piesaistās α4β1 integrīnam, bloķējot mijiedarbību ar tam radniecisko receptoru, asinsvadu šūnu piesaistīšanas molekulu-1 (VCAM 1), ligandu osteopontīnu un alternatīvi savīto domēnu fibronektīnu, tā savienošanās segmentu-1(CS 1). Natalizumabs bloķē α4β7 integrīna mijiedarbību ar tā gļotādu šūnu adhēzijas molekulu-1 (MadCAM 1). Šīs molekulārās mijiedarbības pārraušana novērš vienkodola leikocītu pārvietošanos cauri endotēlijam iekaisušajos parenhīmas audos. Turpmākais natalizumaba darbības mehānisms varētu būt esošo iekaisuma reakciju nomākšana slimajos audos, kavējot α4 leikocītu mijiedarbību ar to ligandiem parenhīmas šūnu ārpusšūnu matricē un parenhīmas šūnās. Šādā veidā natalizumabs var darboties nomācoši uz iekaisuma reakcijām slimajā vietā un kavēt turpmāku imūnsistēmas šūnu nonākšanu iekaisušajos audos.
Krona slimības gadījumos, mijiedarbība starp abiem 41 un 47 integrīniem un endotēlija receptoriem VCAM-1 un MadCAM-1 ir nozīmīgs šai slimībai raksturīgo hronisku iekaisumu veicinošais faktors. MadCAM-1 galvenokārt izdala zarnu endotēlija šūnas un tam ir ārkārtīgi nozīmīga loma T limfocītu piesaistē zarnu limfātiskajiem audiem Peijera plātnītēs. Normālos apstākļos zarnu endotēlija šūnas parasti neizdala VCAM-1. Tomēr, iekaisumu attīstību veicinošo citokīnu klātbūtnē tiek aktivizēts VCAM-1, tādējādi reaģējot uz iekaisuma citokīnu iedarbību, attīstoties Krona slimībai. Šīs šūnu adhēzijas molekulārās mijiedarbības pārtraukšana novērš vienkodola leikocītu pārvietošanos cauri endotēlijam un iekaisušajos parenhīmas audos. Bez tam, 4-subvienības inhibīcija bloķē leikocītu mijiedarbību zarnu ārpusšūnu matriksā, t.sk. osteopontīna un fibronektīna epitopu (FN). Tas var palīdzēt nomākt iekaisuma procesus zarnu audos.
|
More Less | | MA-Ventspils University, Latvia | | Years of translation experience: 8. Registered at ProZ.com: Jan 2005. | | N/A | | N/A | | N/A | | Adobe Acrobat, Microsoft Excel, Microsoft Word, Powerpoint, SDL TRADOS | | About me
Medical, pharmaceutical translations
|
Keywords: Medical, pharmaceutical translations
Chemistry, biochemistry, medicine, pharmaceuticals, veterinary medicine, veterinary science, linguistic validation
Profile last updated
Jan 18 |
The translation workplace 
Expertise 